Pipeline
Sensei is developing a pipeline of investigational medicines that alter the relationship between host immune cells and cancer so that the immune system recognizes tumors as a threat and unleashes an immune response.
TMAb™ Programs
The TMAb platform enables highly selective targeting of immune cells in the tumor microenvironment without on-target off-tumor activity.
Program
Target
Indication
Discovery
Preclinical
Phase I
Phase II